title: [New drugs in the treatment of multiple myeloma].
abstract: Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications. New drugs have been developed including new alkylating agents, proteasome inhibitors and immunomodulators but also monoclonal antibodies and drugs with new mechanisms of action. Hopefully, this new generation of targeted agents will improve the results of the initial therapy, avoid relapses and development of resistances and provide better and less toxic options for the relapsed and refractory patient.
authors.affiliation: Servicio de Hematología clínica y Unidad de investigación Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, España. Electronic address: albiang@gmail.com.
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.affiliation: Servicio de Hematología clínica y Unidad de investigación Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, España.
authors.forename: Cristina
authors.initials: C
authors.lastname: Motlló
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D015507:Drugs, Investigational / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D015507:Drugs, Investigational; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D009588:Nitrogen Mustard Compounds; D011480:Protease Inhibitors; D047428:Protein Kinase Inhibitors; D013792:Thalidomide; D000069461:Bendamustine Hydrochloride; C467566:pomalidomide
keywords: Mieloma múltiple; Multiple myeloma; New drugs; Nuevos fármacos; Targeted therapy; Terapias dirigidas